Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Metabolism: Clinical and Experimental

• Publication date

  1997-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0026-0495(97)90264-XPMID 9284882
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diabetic microvascular complications and growth factors.

  2009cited by this paper
• Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment.

  1996cited by this paper
• Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor.

  1996cited by this paper
• Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor

  1996cited by this paper
• Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes

  1996cited by this paper
• Troglitazone Prevents Glucose-Induced Insulin Resistance of Insulin Receptor in Rat-1 Fibroblasts

  1994cited by this paper
• Antihypertensive effects of CS-045 treatment in obese Zucker rats.

  1993cited by this paper
• The link between hyperglycaemia and diabetic nephropathy

  1992cited by this paper
• Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects

  1992cited by this paper
• Effects of Polyol-Pathway Inhibition and Dietary myo-Inositol on Glomerular Hemodynamic Function in Experimental Diabetes Mellitus in Rats

  1991cited by this paper
• Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease.

  1991cited by this paper
• Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob/ob Mice and Zucker Fatty Rats

  1988cited by this paper

• Renal gluconeogenesis in insulin resistance: A culprit for hyperglycemia in diabetes

  2021cites this paper
• Nuclear Receptors and Transcription Factors in Obesity-Related Kidney Disease.

  2021cites this paper
• Insulin: Trigger and Target of Renal Functions

  2020cites this paper
• Pleiotropic effects of anti-diabetic drugs: A comprehensive review.

  2020cites this paper
• Regulation of Prostaglandin Synthesis

  2017cites this paper
• Diabetic nephropathy: landmark clinical trials and tribulations.

  2016cites this paper
• New molecular insights in diabetic nephropathy

  2016cites this paper
• Pathogenesis and Novel Treatment from the Mouse Model of Type 2 Diabetic Nephropathy

  2013cites this paper
• The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes

  2012cites this paper
• Thiazolidinediones in Type 2 Diabetes Mellitus

  2012cites this paper
• Glomerulonephritis and Cellular Regulation of Prostaglandin Synthesis

  2011cites this paper
• New approaches to the treatment of nephropathy in diabetes

  2011cites this paper
• PPARγ Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial Fibrosis

  2009cites this paper
• Peroxisome proliferator-activated receptors and renal diseases.

  2009cites this paper
• PPAR Agonists and Cardiovascular Disease in Diabetes

  2008cites this paper
• Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.

  2008cites this paper
• Obesity and chronic kidney disease: therapeutic implications

  2007cites this paper
• Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.

  2007cites this paper
• Effects of Troglitazone on the Expression of VEGF and TGF-β in Cultured Rat Mesangial Cells

  2007cites this paper
• Effets néphroprotecteurs des glitazones

  2007cites this paper
• PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.

  2006cites this paper
• PPAR-γ Ligands and Diabetic Nephropathy

  2006cites this paper
• PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse

  2006cites this paper
• Prevention of Progression in Diabetic Nephropathy

  2006cites this paper
• The effects of thiazolidinediones on blood pressure levels – A systematic review

  2006cites this paper
• Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.

  2006cites this paper
• Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1.

  2006cites this paper
• Thiazolidinediones and Progression of Renal Disease in Patients with Diabetes

  2006cites this paper
• Mechanisms in Diabetic Nephropathy Prevention of Progression in Diabetic Nephropathy

  2006cites this paper
• Emerging drugs for diabetic nephropathy

  2005cites this paper
• Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.

  2005cites this paper
• The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension.

  2005cites this paper
• PPARs in diseases: control mechanisms of inflammation.

  2005cites this paper
• The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion.

  2005cites this paper
• Pleiotropic effects of thiazolidinediones: Taking a look beyond antidiabetic activity

  2004cites this paper
• Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses.

  2004cites this paper
• Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome.

  2004cites this paper
• Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice.

  2004cites this paper
• Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney.

  2004cites this paper
• Antiproliferative effect of fluvastatin and thiazolidinedione in mesangial cells of diabetic rats

  2003cites this paper
• Peroxisome Proliferator-Activated Receptor γ Agonist Provides Superior Renal Protection versus Angiotensin-Converting Enzyme Inhibition in a Rat Model of Type 2 Diabetes with Obesity

  2003cites this paper
• Troglitazone Inhibits Isolated Cell Proliferation, and Induces Apoptosis in Isolated Rat Mesangial Cells

  2003cites this paper
• Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al

  2003cites this paper
• Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.

  2003cites this paper
• PPARγ Agonists and Vascular Risk Factors: Potential Effects on Cardiovascular Disease

  2003cites this paper
• A novel peroxisome proliferator-activated receptor (PPAR)gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARgamma activation.

  2003cites this paper
• Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.

  2002cites this paper
• Biphasic vasodilator action of troglitazone on the renal microcirculation.

  2002cites this paper
• Cardiovascular Effects of Thiazolidinediones

  2002cites this paper
• Activation of Peroxisome Proliferator-Activated Receptor-g Inhibits Apoptosis Induced by Serum Deprivation in LLC-PK1 Cells

  2002cites this paper
• Effects of thiazolidinediones on cardiovascular risk factors

  2002cites this paper
• Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.

  2001cites this paper
• Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature.

  2001cites this paper
• Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria

  2001cites this paper
• Expression and Function of Peroxisome Proliferator – Activated Receptor-g in Mesangial Cells

  2001cites this paper
• Peroxisome proliferator-activated receptor-γ activity is associated with renal microvasculature

  2001cites this paper
• Expression and Function of Peroxisome Proliferator–Activated Receptor-γ in Mesangial Cells

  2001cites this paper
• Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure

  2001cites this paper
• Nonhypoglycemic Effects of Thiazolidinediones

  2001cites this paper
• Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.

  2001cites this paper
• Inhibitory effect of troglitazone on tumor necrosis factor alpha-induced expression of monocyte chemoattractant protein-1 in human mesangial cells.

  2000cites this paper
• Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats.

  2000cites this paper
• Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation.

  2000cites this paper
• Obesity: Pathology and Therapy

  2000cites this paper
• Troglitazone enhances glycolysis and improves intracellular glucose metabolism in rat mesangial cells.

  2000cites this paper
• Troglitazone and related compounds: therapeutic potential beyond diabetes.

  2000cites this paper
• Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion.

  2000cites this paper
• Renal protective effect of troglitazone in Wistar fatty rats.

  2000cites this paper
• Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients.

  2000cites this paper
• Thiazolidinediones: a new class of antidiabetic drugs

  1999cites this paper
• New therapeutic approaches to reversing insulin resistance.

  1998cites this paper
• Effect of Troglitazene on Microalbuminuria in Patients With Incipient Diabetic Nephropathy

  1998cites this paper
• Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

  1998cites this paper
• Review Article Peroxisome Proliferator-activated Receptors in Diabetic Nephropathy

  year unknowncites this paper